ArticleScientific reports2017
Lactobacillus johnsonii ameliorates intestinal, extra-intestinal and systemic pro-inflammatory immune responses following murine Campylobacter jejuni infection.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- A naturally isolated symbioticCurrent research in microbial sciences · 2026Article
- Whole-Genome Sequencing of Blood-Isolated Lactobacillus johnsonii in Thailand: Clinical Implications and Public Health Relevance.The American journal of case reports · 2025Article
- Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.NPJ biofilms and microbiomes · 2025Review
- Unveiling the potential ofFrontiers in microbiology · 2025Review
- Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025Review
- Role of the gut microbiota in tumorigenesis and treatment.Theranostics · 2024Review
- Investigation of Trehalose Supplementation ImpactingVeterinary sciences · 2023Article
- Microbiome Alterations Driven byMicrobiology spectrum · 2023Article
- Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injuryActa pharmaceutica Sinica. B · 2023Article
- Review
- Metabolomic signatures of intestinal colonization resistance againstFrontiers in microbiology · 2023Article
- Garlic-Derived Metabolites Exert Antioxidant Activity, Modulate Gut Microbiota Composition and LimitAntioxidants (Basel, Switzerland) · 2022Article
- Anti-Foodborne pathogens and disease · 2022Review
- Antibiotic Treatment during Pregnancy Alters Offspring Gut Microbiota in a Sex-Dependent Manner.Biomedicines · 2022Article
- Genome Sequence and Assessment of Safety and Potential Probiotic Traits ofMicroorganisms · 2022Article
- Activation of Proneuronal Transcription Factor Ascl1 in Maternal Liver Ensures a Healthy Pregnancy.Cellular and molecular gastroenterology and hepatology · 2022Article
- Bacterial and Fungal Adaptations in Cecum and Distal Colon of Piglets Fed With Dairy-Based Milk Formula in Comparison With Human Milk.Frontiers in microbiology · 2022Article
- Serum Untargeted Metabolism Reveals the Mechanism ofNutrients · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Campylobacter jejuni infections are progressively increasing worldwide. Probiotic treatment might open novel therapeutic or even prophylactic approaches to combat campylobacteriosis. In the present study secondary abiotic mice were generated by broad-spectrum antibiotic treatment and perorally reassociated with a commensal murine Lactobacillus johnsonii strain either 14 days before (i.e. prophylactic regimen) or 7 days after (i.e. therapeutic regimen) peroral C. jejuni strain 81-176 infection. Following peroral reassociation both C. jejuni and L. johnsonii were able to stably colonize the murine intestinal tract. Neither therapeutic nor prophylactic L. johnsonii application, however, could decrease intestinal C. jejuni burdens. Notably, C. jejuni induced colonic apoptosis could be ameliorated by prophylactic L. johnsonii treatment, whereas co-administration of L. johnsonii impacted adaptive (i.e. T and B lymphocytes, regulatory T cells), but not innate (i.e. macrophages and monocytes) immune cell responses in the intestinal tract. Strikingly, C. jejuni induced intestinal, extra-intestinal and systemic secretion of pro-inflammatory mediators (such as IL-6, MCP-1, TNF and nitric oxide) could be alleviated by peroral L. johnsonii challenge. In conclusion, immunomodulatory probiotic species might offer valuable strategies for prophylaxis and/or treatment of C. jejuni induced intestinal, extra-intestinal as well as systemic pro-inflammatory immune responses in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.